<DOC>
	<DOC>NCT01971502</DOC>
	<brief_summary>The objective of the single rising dose part (SRD) is to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising doses of BI 1060469 in healthy male subjects. The objective of the food effect part (FE) is to investigate the relative bioavailability of BI 1060469 tablets in healthy male subjects in fed or fasted state.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: 1. Healthy males based upon a complete medical history, including a physical examination, vital signs (blood pressure, pulse rate), 12lead electrocardiogram, and clinical laboratory tests 2. Age within the range of 18 to 50 years 3. Body mass index within the range of 18.5 and 29.9 kg/m2 4. Signed and dated written informed consent prior to admission to the study in accordance with good clinical practice (GCP) and local legislation. Exclusion criteria: 1. Any finding in the medical examination (including blood pressure (BP), pulse rate (PR) or electrocardiogram (ECG)) deviating from normal and judged clinically relevant by the investigator. Pulse rate outside the range of 5090 bpm or blood pressure outside the ranges of 90140 for systolic and 5090 mmHg for diastolic blood pressure if confirmed by repeat measurement. 2. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance 3. In the SRD: serum creatinine laboratory value outside the normal range 4. Glomerular filtration rate (GFR) according to CKDEPI (Chronic Kidney Disease Epidemiology Collaboration)Formula &lt; 60 ml/ min 5. Current or history of relevant kidney, urinary tract diseases or abnormalities (i.e. nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal failure, infections) 6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 7. Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>